Journal
JOURNAL OF PHARMACY AND PHARMACOLOGY
Volume 70, Issue 2, Pages 151-158Publisher
WILEY
DOI: 10.1111/jphp.12824
Keywords
gastrointestinal cancer; heat-shock protein-90; pharmacological inhibitors
Categories
Funding
- MUMS [941614]
Ask authors/readers for more resources
Objectives Heat-shock protein-90 (HSP90) chaperone machinery is critical to the folding, stability and activity of several client proteins including many responsible for tumour initiation, progression and metastasis. Overexpression of HSP90 is correlated with poor prognosis of GI cancer. Key findings Pharmacological inhibitors of HSP90 suppress tumorigenic effects of HSP90 by suppressing angiogenesis, survival, metastasis and drug resistance in GI cancer. This review summarizes the role of HSP90 inhibitors in the treatment of GI cancer. Summary We have presented different antitumour mechanisms of HSP90 inhibitors in cancer treatment. Suppression of HSP90 signalling via specific and novel pharmacological inhibitors is a potentially novel therapeutic approach for patients with GI cancer for a better understanding and hence a better management of this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available